LJI308 is a Pan-Ribosomal S6 Kinase (RSK) Inhibitor
The cold shock protein Y-box binding protein-1 (YB-1) is a multifunctional protein. It shows relations in cell proliferation, survival, and stress response. Through translation and transcription of key proteins and regulation of DNA repair, YB-1 performs its functions in different cancers. YB-1 displays overexpression in many tumor entities, especially...
M2698 is an Orally Active, ATP-Competitive, Selective, Dual p70S6K and Akt Inhibitor
The disorder of PI3K/Akt/mTOR (PAM) signaling pathway occurs in about 30% of human cancers, making it a reasonable target for new therapies. Specifically, the pathway is an important regulator of growth, proliferation, and metabolism. However, some PAM pathway inhibitors, such as Rapamycin complex (mTORC) rapalogs, cause the impairment of...
BAY-985 is an Orally Active and ATP-Competitive TBK1/IKKε Inhibitor
The serine/threonine kinase TBK1 (TANK-binding kinase 1) and its homolog IKKε plays an important role in cellular pathways. And, as we all know, these kinases belong to the nuclear factor κB family. In this article, we will introduce a highly potent, orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε,...
BRD7389, a RSK Family Inhibitor, Induces Insulin Expression in Pancreatic α Cells
Colon cancer is one of the leading causes of cancer deaths worldwide. Multiple genetic alterations may cause colon cancer. The p90 ribosomal S6 kinases (RSKs) are a group of serine/threonine kinases. RSKs regulate a wide range of target proteins, implicating RSKs in the control of cell cycle progression, protein...